PLoS One. 2010 Sep 27;5(9):e12986. doi: 10.1371/journal.pone.0012986.
This paper presents the findings of a study to assess the effectiveness and sustainability of a GAVI (Global Alliance of Vaccines and Immunization) sponsored, time-limited Injection Safety (INS) support. The support came in two forms: 1) in-kind, in the form of AD syringes and safety boxes, and 2) in cash, for those countries that already had a secure, multi-year source of AD syringes and safety boxes, but proposed to use INS support to strengthen their injection safety activities. In total, GAVI gave INS support for a three-year period to 58 countries: 46 with commodities and 12 with cash support. To identify variables that might be associated with financial sustainability, frequencies and cross-tabulations were run against various programmatic and socio-economic variables in the 58 countries. All but two of the 46 commodity-recipient countries were able to replace and sustain the use of AD syringes and safety boxes after the end of their GAVI INS support despite the fact that standard disposable syringes are less costly than ADs (10-15 percent differential). In addition, all 12 cash-recipient countries continued to use AD syringes and safety boxes in their immunization programs in the years following GAVI INS assistance. At the same time, countries were often not prepared for the increased waste management requirements associated with the use of the syringes, suggesting the importance of anticipating challenges with the introduction of new technologies. The sustained use of AD syringes in countries receiving injection safety support from GAVI, in a majority of cases through government financing, following the completion of three years of time-limited support, represents an early indication of how GHPs can contribute to improved health outcomes in immunization safety in the world's poorest countries in a sustainable way.
本文介绍了一项评估全球疫苗免疫联盟(GAVI)资助的、有时间限制的注射安全(INS)支持的有效性和可持续性的研究结果。支持以两种形式提供:1)实物形式,提供 AD 注射器和安全盒,2)现金形式,提供给已经有安全、多年来源的 AD 注射器和安全盒,但提议利用 INS 支持来加强其注射安全活动的国家。总共有 58 个国家获得了 GAVI 的 INS 支持,为期三年:46 个国家获得了商品,12 个国家获得了现金支持。为了确定可能与财务可持续性相关的变量,对 58 个国家的各种方案和社会经济变量进行了频率和交叉制表分析。尽管标准一次性注射器比 AD 注射器便宜 10-15%(10-15%的差价),但在 GAVI INS 支持结束后,除了两个国家外,46 个获得商品的国家都能够替换并维持 AD 注射器和安全盒的使用。此外,在 GAVI INS 援助后的几年里,所有 12 个获得现金的国家都继续在其免疫规划中使用 AD 注射器和安全盒。同时,各国通常没有为与使用注射器相关的增加的废物管理要求做好准备,这表明在引入新技术时预测挑战的重要性。在接受 GAVI 注射安全支持的国家中,在大多数情况下,通过政府供资,在完成三年的限时支持后,继续使用 AD 注射器,这是全球最贫困国家的全球卫生伙伴关系如何能够以可持续的方式为改善免疫安全方面的健康结果做出贡献的早期迹象。